Latest

5 stories

Hide weekly roundups

Yesterday

BioMarin and Ascendis sign settlement and license agreement over CNP patents

The September 24, 2026 agreement resolves patent litigation and grants Ascendis a non-exclusive license to BioMarin patents covering TransCon CNP, with royalties running through May 2030.

SEC filing

Monday, August 31

PartnershipAscendis Pharma A/S Biomarin Pharmaceutical Inc navepegritide

BioMarin and Ascendis settle global patent dispute over Yuviwel

Ascendis will pay BioMarin royalties on Yuviwel sales in the U.S., EU, Brazil and South Korea under a binding term sheet signed August 30, 2026.

SEC filing

Thursday, August 13

Clinical readoutAscendis Pharma A/S navepegritide palopegteriparatide

Ascendis Pharma posts Q2 2026 revenue of €315 million, up 105% year over year

Growth was driven by YORVIPATH and a new YUVIWEL launch, while a PRV sale and note conversion reshaped the balance sheet.

SEC filing

Monday, August 3

Ascendis Pharma Bone's Yorvipath gets labeling supplement approved by FDA

Regulatory decisionAscendis Pharma A/S palopegteriparatide

Thursday, July 16

Ascendis Pharma registers Phase 3 trial of Yorvipath in adolescent hypoparathyroidism

Trial updateAscendis Pharma A/S palopegteriparatide